Koponen Mia Elena, Forget Patrice
Neuroscience with Psychology, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK.
Epidemiology Group, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK.
J Clin Med. 2022 Nov 29;11(23):7060. doi: 10.3390/jcm11237060.
Opioid analgesics are the most effective pharmacological agents for moderate and severe pain. However, opioid use has several limitations such as opioid-induced hyperalgesia (OIH), which refers to the increased pain sensitivity that occurs once analgesia wears off after opioid administration. Several pharmacological interventions have been suggested for OIH, but the current literature does not provide guidelines on which interventions are the most effective and whether they differ depending on the opioid that induces hyperalgesia. This scoping review aimed to identify and describe all the preclinical trials investigating pharmacological interventions for OIH caused by remifentanil, fentanyl, or morphine as the first step towards evaluating whether the most effective OIH interventions are different for different opioids.
Electronic database searches were carried out in Embase, PubMed, and Web of Science. Detailed data extraction was conducted on the eligible trials.
72 trials were eligible for the review. Of these, 27 trials investigated remifentanil, 14 trials investigated fentanyl, and 31 trials investigated morphine. A total of 82 interventions were identified. The most studied interventions were ketamine (eight trials) and gabapentin (four trials). The majority of the interventions were studied in only one trial. The most common mechanism suggested for the interventions was inhibition of N-methyl-D-aspartate (NMDA) receptors.
This scoping review identified plenty of preclinical trials investigating pharmacological interventions for OIH. Using the current literature, it is not possible to directly compare the effectiveness of the interventions. Hence, to identify the most effective interventions for each opioid, the interventions must be indirectly compared in a meta-analysis.
阿片类镇痛药是治疗中度和重度疼痛最有效的药物。然而,阿片类药物的使用存在一些局限性,如阿片类药物诱导的痛觉过敏(OIH),即阿片类药物给药后镇痛作用消失时出现的疼痛敏感性增加。针对OIH已经提出了几种药物干预措施,但目前的文献并未提供关于哪些干预措施最有效以及它们是否因诱导痛觉过敏的阿片类药物不同而有所差异的指导方针。本综述旨在识别和描述所有调查瑞芬太尼、芬太尼或吗啡所致OIH的药物干预措施的临床前试验,作为评估不同阿片类药物最有效的OIH干预措施是否不同的第一步。
在Embase、PubMed和Web of Science中进行电子数据库检索。对符合条件的试验进行详细的数据提取。
72项试验符合综述要求。其中,27项试验研究瑞芬太尼,14项试验研究芬太尼,31项试验研究吗啡。共确定了82种干预措施。研究最多的干预措施是氯胺酮(8项试验)和加巴喷丁(4项试验)。大多数干预措施仅在一项试验中进行了研究。干预措施最常见的作用机制是抑制N-甲基-D-天冬氨酸(NMDA)受体。
本综述识别出大量调查OIH药物干预措施的临床前试验。根据当前文献,无法直接比较这些干预措施的有效性。因此,为了确定每种阿片类药物最有效的干预措施,必须在荟萃分析中间接比较这些干预措施。